uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Sundin, Anders
Alternative names
Publications (10 of 186) Show all publications
Ramage, J. K., Valle, J., Nieveen van Dijkum, E. J., Sundin, A., Pascher, A., Couvelard, A. & Kloeppel, G. (2019). Colorectal Neuroendocrine Neoplasms - areas of unmet need. Neuroendocrinology, 108(1), 45-53
Open this publication in new window or tab >>Colorectal Neuroendocrine Neoplasms - areas of unmet need
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 45-53Article in journal (Refereed) Published
Abstract [en]

The subject of colorectal neuroendocrine neoplasms (NENs), subdivided into well-differentiated NENs, termed neuroendocrine tumours (NETs; grade (G) 1 and 2), and poorly differentiated NENs, termed neuroendocrine carcinomas (NECs; G3) according to the 2010 World Health Organisation (WHO) classification, has arguably not had as much attention or study as NENs occurring in other sites. Colorectal NETs and NECs are however easier to study than many others since they are usually not difficult to remove and are increasingly detected because of intensified colorectal cancer screening and surveillance programmes. Colorectal NETs and NECs show site-specific heterogeneity with variable behaviour and different therapeutic options; these various aspects provide unique challenges. Because of bowel cancer screening programmes, colorectal NENs, like conventional adenocarcinomas, may be diagnosed at a stage that is associated with improved survival. In this article we intend to describe and define areas of unmet needs relating to the epidemiology, classification, pathology, diagnosis and therapy of colorectal NETs (including NETs G3), colorectal NECs, and finally, mixed adeno-neuroendocrine carcinomas (MANECs) by reviewing and discussing the relevant literature.

Keywords
Carcinoid tumours, Gastroenteropancreatic neuroendocrine tumours, Neuroendocrine tumour, Somatostatin receptor
National Category
Cancer and Oncology Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-362622 (URN)10.1159/000493767 (DOI)000456048400006 ()30219817 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan.

Available from: 2018-10-08 Created: 2018-10-08 Last updated: 2019-02-11Bibliographically approved
Lindström, E., Velikyan, I., Regula, N. K., Alhuseinalkhudhur, A., Sundin, A., Sörensen, J. & Lubberink, M. (2019). Regularized reconstruction of digital time-of-flight Ga-68-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients. Theranostics, 9(12), 3476-3484
Open this publication in new window or tab >>Regularized reconstruction of digital time-of-flight Ga-68-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients
Show others...
2019 (English)In: Theranostics, ISSN 1838-7640, E-ISSN 1838-7640, Vol. 9, no 12, p. 3476-3484Article in journal (Refereed) Published
Abstract [en]

Accurate localization of recurrent prostate cancer (PCa) is critical, especially if curative therapy is intended. With the aim to optimize target-to-background uptake ratio in Ga-68-PSMA-11 PET, we investigated the image quality and quantitative measures of regularized reconstruction by block-sequential regularized expectation maximization (BSREM).

Methods:

The study encompassed retrospective reconstruction and analysis of 20 digital time-of-flight (TOF) PET/CT examinations acquired 60 min post injection of 2 MBq/kg of Ga-68-PSMA-11 in PCa patients with biochemical relapse after primary treatment. Reconstruction by ordered-subsets expectation maximization (OSEM; 3 iterations, 16 subsets, 5 mm gaussian postprocessing filter) and BSREM (beta-values of 100-1600) were used, both including TOF and point spread function (PSF) recovery. Background variability (BV) was measured by placing a spherical volume of interest in the right liver lobe and defined as the standard deviation divided by the mean standardized uptake value (SUV). The image quality was evaluated in terms of signal-to-noise ratio (SNR) and signal-to-background ratio (SBR), using SUVmax of the lesions. A visual assessment was performed by four observers.

Results:

OSEM reconstruction produced images with a BV of 15%, whereas BSREM with a beta-value above 300 resulted in lower BVs than OSEM (36% with beta 100, 8% with beta 1300). Decreasing the acquisition duration from 2 to 1 and 0.5 min per bed position increased BV for both reconstruction methods, although BSREM with beta-values equal to or higher than 800 and 1200, respectively, kept the BV below 15%. In comparison of BSREM with OSEM, the mean SNR improved by 25 to 66% with an increasing beta-value in the range of 200-1300, whereas the mean SBR decreased with an increasing beta-value, ranging from 0 to 125% with a beta-value of 100 and 900, respectively. Decreased acquisition duration resulted in beta-values of 800 to 1000 and 1200 to 1400 for 1 and 0.5 min per bed position, respectively, producing improved image quality measures compared with OSEM at a full acquisition duration of 2 min per bed position. The observer study showed a slight overall preference for BSREM beta 900 although the interobserver variability was high.

Conclusion:

BSREM image reconstruction with beta-values in the range of 400-900 resulted in lower BV and similar or improved SNR and SBR in comparison with OSEM.

Keywords
Ga-68-PSMA-11, prostate cancer, PET/CT, image reconstruction, BSREM, interobserver variability
National Category
Medical Image Processing
Identifiers
urn:nbn:se:uu:diva-388045 (URN)10.7150/thno.31970 (DOI)000469953000006 ()
Available from: 2019-06-26 Created: 2019-06-26 Last updated: 2019-06-26Bibliographically approved
Sundin, A., Fanti, S., Giammarile, F. & de Herder, W. W. (2019). Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their "Letter to the Editor".. Neuroendocrinology, 108(4), 366-366
Open this publication in new window or tab >>Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their "Letter to the Editor".
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 4, p. 366-366Article in journal (Refereed) Published
Place, publisher, year, edition, pages
S. Karger, 2019
National Category
Neurology Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-382949 (URN)10.1159/000497419 (DOI)000471962300010 ()30917382 (PubMedID)
Available from: 2019-05-07 Created: 2019-05-07 Last updated: 2019-08-05Bibliographically approved
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R. T., Knigge, U. P., . . . Pavel, M. E. (2019). Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. Neuroendocrinology, 108(1), 18-25
Open this publication in new window or tab >>Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 18-25Article in journal (Refereed) Published
Abstract [en]

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

Keywords
Biomarkers, Imaging, Metastasis, Neuroendocrine neoplasms, Therapy, Unmet medical needs
National Category
Endocrinology and Diabetes Psychiatry
Identifiers
urn:nbn:se:uu:diva-375573 (URN)10.1159/000493319 (DOI)000456048400003 ()30153686 (PubMedID)
Note

ENETS 2016 Munich Advisory Board Participants, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan.

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Baudin, E., Hayes, A. R., Scoazec, J.-Y., Filosso, P. L., Lim, E., Kaltsas, G., . . . Caplin, M. E. (2019). Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. Neuroendocrinology, 108(1), 7-17
Open this publication in new window or tab >>Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 7-17Article in journal (Refereed) Published
Abstract [en]

Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

Keywords
Bronchial carcinoid tumours, NET, Neuroendocrine neoplasms, Pulmonary carcinoids
National Category
Endocrinology and Diabetes Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-375567 (URN)10.1159/000493980 (DOI)000456048400002 ()30248673 (PubMedID)
Note

ENETS 2016 Munich Advisory Board Participants (UU authors): Jenny Falkerby; Anders Sundin; Eva Tiensuu Janson & Staffan Welin

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Jensen, R. T., Bodei, L., Capdevila, J., Couvelard, A., Falconi, M., Grozinsky-Glasberg, S., . . . Fazio, N. (2019). Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms. Neuroendocrinology, 108(1), 26-36
Open this publication in new window or tab >>Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 26-36Article in journal (Refereed) Published
Abstract [en]

Recently, the European Neuroendocrine Tumor Society (ENETS) held working sessions composed of members of the advisory board and other neuroendocrine neoplasm (NEN) experts to attempt to identify unmet needs in NENs in different locations or with advanced/poorly differentiated NENs. This report briefly summarizes the main proposed areas of unmet needs in patients with functional and nonfunctional pancreatic NENs.

National Category
Endocrinology and Diabetes Neurosciences
Identifiers
urn:nbn:se:uu:diva-362648 (URN)10.1159/000494258 (DOI)000456048400004 ()30282083 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan

Available from: 2018-10-08 Created: 2018-10-08 Last updated: 2019-02-11Bibliographically approved
Sorbye, H., Baudin, E., Borbath, I., Caplin, M., Chen, J., Cwikla, J. B., . . . Garcia-Carbonero, R. (2019). Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology, 108(1), 54-62
Open this publication in new window or tab >>Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 54-62Article in journal (Refereed) Published
Abstract [en]

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

Keywords
Neuroendocrine carcinoma, Neuroendocrine neoplasm, Neuroendocrine tumor
National Category
Neurosciences Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-375598 (URN)10.1159/000493318 (DOI)000456048400007 ()30153658 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan.

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Jahn, U., Ilan, E., Sandström, M., Garske-Román, U., Velikyan, I., Fröss-Baron, K., . . . Sundin, A. (2018). 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors. Paper presented at 31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), OCT 13-17, 2018, Dusseldorf, GERMANY. European Journal of Nuclear Medicine and Molecular Imaging, 45, S61-S62
Open this publication in new window or tab >>177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors
Show others...
2018 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 45, p. S61-S62Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Springer, 2018
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:uu:diva-372962 (URN)000449266200098 ()
Conference
31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), OCT 13-17, 2018, Dusseldorf, GERMANY
Available from: 2019-01-14 Created: 2019-01-14 Last updated: 2019-01-14Bibliographically approved
Dam, G., Grønbæk, H., Sørbye, H., Thiis-Evensen, E., Paulsson, B., Sundin, A., . . . Tiensuu Janson, E. (2018). A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors. Paper presented at 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 07-09, 2018, Barcelona, SPAIN. Neuroendocrinology, 106(Supplement: 1), 152-152
Open this publication in new window or tab >>A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors
Show others...
2018 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 106, no Supplement: 1, p. 152-152Article in journal, Meeting abstract (Other academic) Published
Keywords
gep-net, ct, cga, correlation
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-355840 (URN)10.1159/000487699 (DOI)000427285300150 ()
Conference
15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 07-09, 2018, Barcelona, SPAIN
Note

Meeting Abstract: F05

Available from: 2018-07-13 Created: 2018-07-13 Last updated: 2018-07-13Bibliographically approved
Sandström, M., Fröss-Baron, K., Khan, T. S., Granberg, D., Sundin, A. & Lubberink, M. (2018). Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving 177Lu-DOTATATE therapy. Paper presented at 31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), OCT 13-17, 2018, Dusseldorf, GERMANY. European Journal of Nuclear Medicine and Molecular Imaging, 45(Supplement 1), S31-S31
Open this publication in new window or tab >>Absorbed doses based on a single measurement point versus three measurement points in 600 patients with neuroendocrine tumours receiving 177Lu-DOTATATE therapy
Show others...
2018 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 45, no Supplement 1, p. S31-S31Article in journal, Meeting abstract (Other academic) Published
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:uu:diva-373335 (URN)10.1007/s00259-018-4148-3 (DOI)000449266200039 ()
Conference
31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), OCT 13-17, 2018, Dusseldorf, GERMANY
Note

Meeting Abstract: OP-076

Available from: 2019-01-14 Created: 2019-01-14 Last updated: 2019-01-14Bibliographically approved
Organisations

Search in DiVA

Show all publications